Drug reference

Lanadelumab

Hemostatic · Prevention of Hereditary Angioedema

HemostaticPrevention of Hereditary Angioedema

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

Manufacturer advises preferable to avoid—limited or no information available; animal studies do not indicate toxicity.

FDA category + note

Mechanism

Lanadelumab is a humanised monoclonal antibody which inhibits plasma kallikrein activity, thereby limiting the production of bradykinin, a potent vasodilator associated with angioedema attacks in patients with hereditary angioedema.

Indications

Prevention of recurrent attacks of hereditary angioedema (initiated under specialist supervision)

Dosing

Adult: 300 mg every 2 weeks, reduced to 300 mg every 4 weeks in those stable and attack free, by subcutaneous injection. Consult product literature.

Side effects

Common

Dizzinesshypersensitivitymyalgiaoral disordersskin reactions

Pregnancy & lactation

Pregnancy

Manufacturer advises preferable to avoid—limited or no information available; animal studies do not indicate toxicity.

Lactation

Manufacturer advises avoid during ﬁrst few days after birth—possible risk from transfer of antibodies to infant. After this time, use during breastfeeding only if clinically needed.